^Chen W, Gueron M (1992). “The inhibition of bovine heart hexokinase by 2-deoxy-d-glucose-6-phosphate: Characterization by 31P NMR and metabolic implications”. Biochimie74: 867–873. doi:10.1016/0300-9084(92)90070-U. PMID1467345.
^M Ralser, MM Wamelink, EA Struys, C Joppich, S Krobitsch, C Jakobs, H Lehrach (2008). “A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth”. Proc. Natl. Acad. Sci. U. S. A.105 (46): 17807-17811. doi:10.1073/pnas.0803090105.
^Pelicano, H; Martin, DS; Xu, RH; Huang, P (2006). “Glycolysis inhibition for anticancer treatment”. Oncogene25 (34): 4633–4646. doi:10.1038/sj.onc.1209597. PMID16892078.
^Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ (2013). “A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors”. Cancer Chemother Pharmacol71 (2): 523-530. doi:10.1007/s00280-012-2045-1. PMID23228990.
^Garriga-Canut, M.; Schoenike, B.; Qazi, R.; Bergendahl, K.; Daley, T. J.; Pfender, R. M.; Morrison, J. F.; Ockuly, J.; Stafstrom, C.; Sutula, T.; Roopra, A. (2006). “2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP–dependent metabolic regulation of chromatin structure”. Nat. Neurosci.9: 1382 - 1387. doi:10.1038/nn1791. PMID17041593.